Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Alba Herrero-Morant¹, Jon Zubiaur-Zamacola², Adrián Margarida-De Castro², Raquel Pérez-Barquín², Miguel Ángel González-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…
Abstract Number: 0367 • ACR Convergence 2022
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
April Jorge¹, Baijun Zhou¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Patients with SLE are at increased risk of COVID-19 and its severe outcomes, in part due to the use of immunosuppressants. We sought to…
Abstract Number: 0632 • ACR Convergence 2022
Single-cell Multiomic Profiling Differentiates Ancestral B Cell Pathologies Contributing to Lupus Disease Activity
Kevin Thomas, Miles Smith, Samantha Slight-Webb, Susan Macwana, Joseph Kheir, Carla J. Guthridge, Wade deJager, Christian Wright, Bolanle Adebayo, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Genetic ancestry impacts SLE prevalence, clinical presentation, and treatment response; however, the molecular underpinnings of this disparity remain poorly understood. Recent findings demonstrate that…
Abstract Number: 0652 • ACR Convergence 2022
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
Shohei Nakamura, Yuko okamoto, Yasuhiro Katsumata and Masayoshi Harigai, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…
Abstract Number: 0670 • ACR Convergence 2022
A Short Allelic Epitope Coded by HLA-DRB1*03:01 Activates a Systemic Lupus Erythematosus Cell Aberration Cascade
Bruna Miglioranza Scavuzzi¹, Bhavneet Kaur¹, Vincent Van Drongelen¹, Raquel Mesquita-Ferrari², Amr Sawalha³, Frederick Miller⁴ and Joseph Holoshitz¹, ¹University of Michigan, Ann Arbor, MI, ²Universidade Nove de Julho (UNINOVE), São Paulo, Brazil, ³University of Pittsburgh, Pittsburgh, PA, ⁴Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from an interaction of genetic, epigenetic, hormonal, environmental and immunoregulatory influences. It has been well…
Abstract Number: 0956 • ACR Convergence 2022
Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers
Nicola Fraser¹, Mala Masson², Kristina Deonaraine³, Philip Carlucci⁴, Colin Phoon⁵, Ashley Roman⁵, Peter Izmirly⁶, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield⁵, Young Mi Lee⁵, Julie Nusbaum⁷, Bruce Solitar⁵, Fardina Malik⁵, Paula Rackoff¹, Rebecca Haberman¹, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Albuhamad⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Nelangi Pinto¹², Anita Moon-Grady¹³, Lisa Howley¹⁴, Stephanie Levasseur¹⁵, Jyothi Matta¹⁶, Christopher Lindblade¹⁷, Andrew Rubenstein¹⁸, Caitlin Haxel¹⁹, Katherine Kohari²⁰, Joshua Copel²⁰, James Strainic²¹, Tam Doan²², Karla Bermudez-Wagner²², Shreya Sunil Sheth²², Stacy Killen²³, Theresa Tacy²⁴, Michelle Kaplinski²⁴, Bailey Drewes²⁵, Robert Clancy⁶, Bettina Cuneo²⁶ and Jill Buyon⁶, ¹NYU School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³University at Buffalo, Buffalo, NY, ⁴NYU Langone, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, ⁹East Virginia Medical School, Norfolk, VA, ¹⁰University of Kentucky, Lexington, KY, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, ¹³UCSF, San Francisco, ¹⁴Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁵Columbia University, New York, NY, ¹⁶University of Louisville, Louisville, KY, ¹⁷Phoenix Children's Hospital, Phoenix, ¹⁸Dignity Health, Phoenix, ¹⁹University of Vermont Children's Hospital, Burlington, VT, ²⁰Yale University, New Haven, CT, ²¹UH Rainbow Babies, Cleveland, OH, ²²Baylor College of Medicine, Houston, TX, ²³Vanderbilt University, Nashville, TN, ²⁴Stanford University, Stanford, CA, ²⁵University of Colorado, Denver, CO, ²⁶University of Colorado School of Medicine, Aurora, CO
Background/Purpose: While it is well accepted that congenital heart block (CHB) and neonatal annular rash are highly associated with maternal anti-Ro60 and 52 autoantibodies, the…
Abstract Number: 0977 • ACR Convergence 2022
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Jason S Knight¹, Winn Walter Chatham², Christine Henning³, Julia H N Harris⁴, Andre Van Maurik⁵, Roger A Levy⁶ and David Pisetsky⁷, ¹University of Michigan, Division of Rheumatology, Ann Arbor, MI, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL, ³GlaxoSmithKline, Global Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷Duke University Medical Center, Durham, NC
Background/Purpose: Serological and cellular biomarkers are used in clinical practice to guide the management of SLE. Increased levels of anti-dsDNA and decreased levels of complement…
Abstract Number: 0994 • ACR Convergence 2022
Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
Michelle Petri¹, Daniel Joyce², Kristin Haag², Andrea Fava³, Daniel W. Goldman¹, Diana Zhong², Shaoming Xiao⁴, Aaron M. Milstone² and Laurence S Magder⁵, ¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD
Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive…
Abstract Number: 1133 • ACR Convergence 2022
Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus
Cecilia Chung, Gul Karakoc, Jorge Gamboa, Jonathan Mosley, Nancy Cox, Michael Stein and Vivian Kawai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem condition that occurs more frequently in certain racial groups, particularly in populations of African ancestry. Low white…
Abstract Number: 1305 • ACR Convergence 2022
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
Joshua Novack¹, Gregory Chang², Stephen Honig¹, Anmol Monga², Xiaoliu Zhang³, Punam Saha³, Dimitri Martel², Peter Izmirly⁴, H Michael Belmont⁵, Jill Buyon⁴ and Amit Saxena⁵, ¹NYU Langone Health Department of Medicine, New York, NY, ²NYU Langone Health Department of Radiology, New York, NY, ³University of Iowa Departments of Radiology and Electrical and Computer Engineering, Iowa City, IA, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Fractures in patients with systemic lupus erythematosus (SLE) are more common than age and sex matched controls. Fracture risk is traditionally assessed by dual-energy…
Abstract Number: 1384 • ACR Convergence 2022
Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus
Amanda Marsden¹, Georgina Tiller², Angelyne Rivera³, Maitri Deep Rai³, Lori Tucker³, Jaime Guzman⁴, Kimberly Morishita², Kristin Houghton², Shreya Moodley³ and David Cabral⁵, ¹BC Children's Hospital, Castle Hill, Australia, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³British Columbia Children's Hospital, Vancouver, BC, Canada, ⁴University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood onset SLE is an autoantibody mediated, multisystem disease which can include cardiac manifestations. Because cardiac involvement can develop insidiously, an earlier review from…
Abstract Number: 1455 • ACR Convergence 2022
Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus
Gelsomina Alle¹, Marina Scolnik¹, VALERIA SCAGLIONI¹, John Fredy Jaramillo Gallego¹, Mayra Alejandra Tobar Jaramillo¹, Rodolfo Alvarado¹, Enrique R Soriano² and Javier Eduardo Rosa¹, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study is to assess the incidence of Systemic Lupus Erythematosus (SLE) in a cohort of patients with Immune Thrombocytopenic Purpura…
Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Rosa Arvizu-Rivera¹, jiram torres-Ruiz², Alfredo Pérez-Fragoso², Beatriz Alcalá-Carmona³, Miroslava Nuñez-Aguirre⁴, Ana Sofía Vargas-Castro⁴, Abdiel Absalón-Aguilar³, Jaquelin Lira-Luna⁴ and Diana Gómez-Martín², ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²INCMNSZ, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…
Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Ken Yasaka¹, Tomohide Yamazaki², Hiroko Sato¹, Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae⁴, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²SBI Biotech, Tokyo, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…
Abstract Number: 1711 • ACR Convergence 2022
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
Jie An, Xizhang Sun, Lena Tanaka and Keith Elkon, University of Washington, Seattle, WA
Background/Purpose: SLE patients characteristically have a type I interferon (IFN-I) signature in peripheral blood cells and this same signature is prominent in lesional and non-lesional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].